Patents by Inventor Dale B. Schenk

Dale B. Schenk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240254211
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: January 30, 2024
    Publication date: August 1, 2024
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20210032318
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: April 7, 2020
    Publication date: February 4, 2021
    Applicants: Prothena Biosciences Limited, The Regents of the University of California
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20210008185
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 20, 2020
    Publication date: January 14, 2021
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Dale B. SCHENK, Peter A. SEUBERT, Jonathan WALL, José SALDANHA
  • Publication number: 20190300598
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: February 21, 2019
    Publication date: October 3, 2019
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: DALE B. SCHENK, ELIEZER MASLIAH, MANUEL J. BUTTINI, TAMIE J. CHILCOTE, EDWARD M. ROCKENSTEIN, KATE DORA GAMES
  • Publication number: 20180360934
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 20, 2018
    Applicants: PROTHENA THERAPEUTICS LIMITED, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: DALE B. SCHENK, PETER A. SEUBERT, JONATHAN WALL, JOSÉ SALDANHA
  • Publication number: 20170349651
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: May 30, 2017
    Publication date: December 7, 2017
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward M. Rockenstein, Kate Dora Games
  • Publication number: 20170081396
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 20, 2016
    Publication date: March 23, 2017
    Applicants: PROTHENA THERAPEUTICS LIMITED, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: DALE B. SCHENK, PETER A. SEUBERT, JONATHAN WALL, JOSÉ SALDANHA
  • Publication number: 20160184416
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: August 27, 2015
    Publication date: June 30, 2016
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Chilcote J. Tamie, Edward Rockenstein, Kate Dora Games
  • Publication number: 20160060331
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Application
    Filed: August 31, 2015
    Publication date: March 3, 2016
    Inventors: Dale B. Schenk, Eliezer Masliah, Manuel J. Buttini, Chilcote J. Tamie, Edward M. Rockenstein, Kate Dora Games
  • Patent number: 9067981
    Abstract: The present invention provides crystals including amino acids 1-7 of SEQ ID NO:1 and a Fab fragment of 12A11, 12B4, 10D5 or 3D6, as well as of amino acids 1-40 of SEQ ID NO:1 and a Fab fragment of 12A11 or 3D6, as well as methods for preparing the crystals. The present invention also provides a computer implemented method for analyzing binding of a candidate antibody fragment to a peptide including an epitope of amino acids 1-7 of SEQ ID NO:1, a method for identifying an antibody fragment that can mimic the Fab fragment of 12A11, a method for identifying an antibody fragment that can mimic the Fab fragment of 3D6, a method for identifying a candidate antibody fragment that binds to a peptide including an epitope of amino acids 1-7 of SEQ ID NO:1, and a method for designing a humanized antibody that binds to a peptide comprising an epitope of amino acids 1-7 of SEQ ID NO:1.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: June 30, 2015
    Assignees: JANSSEN SCIENCES IRELAND UC, WYETH LLC, THE BOARD OF TRUSTEES OF LELAND STANFORD JR. UNIVERSITY
    Inventors: Guriqbal Basi, Dale B. Schenk, Hadar Hana Feinberg, William I. Weis
  • Publication number: 20150158937
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: June 25, 2014
    Publication date: June 11, 2015
    Applicant: ONCLAVE THERAPEUTICS LIMITED
    Inventors: Dale B. SCHENK, Peter A. SEUBERT, José SALDANHA
  • Patent number: 9051363
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include humanized antibodies.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: June 9, 2015
    Assignees: JANSSEN SCIENCES IRELAND UC, WYETH LLC
    Inventors: Guriq Basi, Jose William Saldanha, Dale B. Schenk
  • Patent number: 9034337
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: May 19, 2015
    Assignee: Prothena Biosciences Limited
    Inventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Publication number: 20140348843
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Application
    Filed: May 28, 2014
    Publication date: November 27, 2014
    Applicant: NEOTOPE BIOSCIENCES LIMITED
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
  • Publication number: 20140341911
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.
    Type: Application
    Filed: January 2, 2014
    Publication date: November 20, 2014
    Inventor: Dale B. Schenk
  • Publication number: 20140227274
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.
    Type: Application
    Filed: September 3, 2013
    Publication date: August 14, 2014
    Applicant: JANSSEN ALZHEIMER IMMUNOTHERAPY
    Inventor: Dale B. Schenk
  • Patent number: 8791243
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: July 29, 2014
    Assignee: Onclave Therapeutics Limited
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, Jose Saldanha
  • Patent number: 8741298
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: June 3, 2014
    Assignee: Neotope Biosciences Limited
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
  • Publication number: 20140134103
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: December 6, 2013
    Publication date: May 15, 2014
    Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José Saldanha
  • Patent number: 8697082
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: April 15, 2014
    Assignees: Neotope Biosciences Limited, The Regents of the University of California
    Inventors: Dale B. Schenk, Eliezer Masliah